FORM AEC-374 (M-3)
(5-72)
10 CFR 30

U. S. ATOMIC ENERGY COMMISSION
BYPRODUCT MATERIAL LICENSE
(Medical - Groups I & II)

License No. 21-13255-01 Page 1 of 2 Pages

Amendment No. 17

Pursuant to the Atomic Energy Act of 1954 and Title 10, Code of Federal Regulations, Chapter 1, Parts 30, 32, 33, 34, and 35, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, own, possess, transfer and import byproduct material listed below; and to use such byproduct material for the purpose(s) and at the place(s) designated below. This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954 as amended, and is subject to all applicable rules, regulations, and orders of the Atomic Energy Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated February 27, 1975,
1. Woodland Medical Group	3. License Number 21-13255-01 is amended in its entirety to read as follows:
2. 22341 W. Eight Mile Road Detroit, Michigan 48219	4. Expiration date May 31, 1979
	5. Reference No.

6. Byproduct material (element and mass number)	7. Chemical and/or physical form	8. Maximum amount of radioactivity which licensee may possess at any one time
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2 curies of each byproduct material authorized in Subitem 6.B.
C. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	C. Any	C. 3 millicuries of each byproduct material authorized in Subitem 6.C.
D. Iodine 131	D. Iodide	D. 30 millicuries
E. Phosphorus 32	E. Soluble Phosphate	E. 10 millicuries
F. Cesium 137	F. Any	F. 100 microcuries

Conditions numbered 1. printed on the reverse side of this page shall apply to this license.

A118

CONDITIONS

1. Byproduct material may only be used at the licensee's address stated in Item 2 above.

2. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 20, "Standards for Protection Against Radiation."

3. Except as otherwise specifically provided by this license, byproduct material to be administered to humans shall be procured in prepackaged, precalibrated form from a supplier who manufactures or repackages the product under appropriate pharmaceutical controls related to assay, identity, quality, purity, sterility, and nonpyrogenicity.

4. Iodine 131 labeled Macroaggregated Iodinated Human Serum Albumin, Chromium 51 labeled Human Serum Albumin, and Iodine 131 labeled Colloidal (Microaggregated) Human Serum Albumin shall be procured from a supplier who holds an unsuspended or unrevoked license issued by the Secretary, Department of Health, Education, and Welfare, to propagate or manufacture and prepare, label, or distribute this material pursuant to Title 42, Chapter 1, Code of Federal Regulations, Part 73, "Biological Products."

5. Needles or standard medical applicator cells containing Cobalt 60 as wire shall not be opened by the licensee unless specifically authorized by a condition in this license.

6. Patients containing Cobalt 60, Cesium 137, and/or Iridium 192 implants shall remain hospitalized until the implants are removed.

7. Patients containing Iodine 131 for the treatment of thyroid carcinoma or patients containing therapeutic quantities of Gold 198 shall remain hospitalized until the residual activity is 30 millicuries or less.

License Number 21-13255-01

Amendment No. 17

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
C. In vitro studies.
D. Treatment of hyperthyroidism and cardiac dysfunction.
E. Treatment of leukemia, polycythemia vera, and bone metastases.
F. Calibration sources.

CONDITIONS

Wherever the words "Atomic Energy Commission" or "Commission" appear in this license, except where the context of their use refers to a fact or event prior to January 19, 1975, they mean the Nuclear Regulatory Commission created by Public Law 93-438 and Executive Order No. 11834.

10. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

11. Byproduct material shall be used by, or under the supervision of, Henry A. Shevitz, M.D. or Stephen H. Sherman, M.D.

12. Byproduct material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations, Part 35.

13. Notwithstanding the requirements of Section 35.14(b) of Title 10, Code of Federal Regulations, Part 35, the licensee may possess and use any by-product material for which he was authorized and that was in his possession on January 13, 1975.

14. Except as specifically provided otherwise by this license, the licensee shall possess and use byproduct material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application received April 30, 1974 and letter dated February 27, 1975.

For The U.S. Nuclear Regulatory Commission
~~For the U.S. Atomic Energy Commission~~
Original Signed By
LEO WADE, JR.

Date APR 3 1975

by Materials Branch
Directorate of Licensing
Washington, D. C. ~~20545~~ 20555

E 1